Biontech feels the pride of China

OWhen the Chinese hear about Biontech, it’s usually nothing good. At the end of April, the short news channel Weibo reported that the German vaccine triggered hepatitis. It’s not true. The studies cited on the fact that some children with hepatitis had previously been vaccinated against Covid do not claim that there is a causal link between the two. Chinese netizens, on the other hand, felt reassured that foreign vaccines cannot be trusted.

It’s no wonder, then, that on Everyday Monday, when the Mainz-based biotech company presented its quarterly figures, respected Shanghai-based business magazine Yicai reported that “phase 2 clinical trials” of the German vaccine in China had just been extended by Beijing regulators until October 30 – the third time after being launched in December 2020. If so, the Chinese shouldn’t be hoping that Biontech will help them live with the virus. After all, the German vaccine with mRNA technology was found to be much more effective than Chinese inactivated vaccines, which have dangerously low efficacy, especially in the elderly.

The fact that China, obviously out of arrogance and revenge because its own vaccines are not approved in Europe, has been preventing the German vaccine for a year and a half now, is at the center of criticism focused from abroad on the brutal blockages in the metropolis of 26 million people shanghai They had no understanding for China’s “zero Covid policy”, Robert Koch Institute President Lothar Wieler and virologist Sandra Ciesek said on Friday at the FAZ congress in Frankfurt . The Financial Times recently said that President Xi Jinping must overcome his “pride” and finally authorize foreign mRNA vaccines such as Biontech and Moderna.

“The people’s war” not only against the virus

The fact that 130 million Chinese over the age of 60 are not vaccinated is the main argument in favor of the confinements, which in the case of Shanghai have lasted for more than a month, and for many inhabitants even twice as long. But currently, only foreigners in expensive private hospitals are given a vaccination appointment. The magazine “Spiegel” had speculated at the end of April that the government now seemed to be considering the German vaccine. Talks between Biontech and Chinese representatives are planned. Last year, Biontech entered into a partnership with the Shanghai conglomerate Fosun for the production of 100 million cans per year. At the beginning of the year, the company assured that it would continue to focus on the huge market. However, the company would not make a statement as to when the vaccine will be approved. Mainz was only told on Monday that as soon as there is news about the approval, it will be announced.

Leave a Comment